Background We performed an updated meta-analysis of randomized placebo-controlled tests tests memantine monotherapy for individuals with Alzheimers disease (Advertisement). function evaluation (SMD=?0.18, 95% CI=?0.27 to ?0.09, p=0.0001), and stage of dementia (SMD=?0.23, 95% CI=?0.33 to ?0.12, p=0.0001) ratings. Memantine was more advanced than placebo with regards to discontinuation due to inefficacy [risk percentage (RR)=0.36, 95%… Continue reading Background We performed an updated meta-analysis of randomized placebo-controlled tests tests